Perceptive Advisors LLC Blueprint Medicines Corp Transaction History

Perceptive Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $61.2 Million - $82.7 Million	-664,574 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $1.6 Million - $2.23 Million	-24,050 Reduced 3.49%	664,574 $61.6 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $3.37 Million - $5.76 Million	70,000 Added 11.32%	688,624 $40.3 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $17.7 Million - $21.9 Million	-264,640 Reduced 29.96%	618,624 $49.6 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $24 Million - $33.4 Million	-329,467 Reduced 27.17%	883,264 $64.9 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $4.29 Million - $5.7 Million	-58,323 Reduced 4.59%	1,212,731 $114 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $20.1 Million - $35.8 Million	413,728 Added 48.26%	1,271,054 $102 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $3.82 Million - $6.22 Million	-83,821 Reduced 8.91%	857,326 $43.5 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $1.18 Million - $1.57 Million	-20,000 Reduced 2.08%	941,147 $73.5 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $4.22 Million - $7.01 Million	-69,287 Reduced 6.72%	961,147 $61 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $8.06 Million - $11.3 Million	-110,000 Reduced 9.65%	1,030,434 $94.5 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $45 Million - $63.2 Million	715,773 Added 168.55%	1,140,434 $86 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $18 Million - $29.6 Million	424,661	424,661 $29.6 Million

352

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.76B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.